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OBJECTIVES The purpose of this study was to determine the frequency and causes of intermittent and
permanent loss of cardiac resynchronization therapy (CRT) in patients who have undergone
the successful implantation of a transvenous defibrillator that delivers CRT (CRT-D).
BACKGROUND The causes of loss of CRT have not been described.
METHODS The records of 512 patients who underwent an attempt at implantation of a transvenous
CRT-D device as part of the VENTAK CHF/CONTAK CD Biventricular Pacing study
were analyzed.
RESULTS Device implantation was successful in 443 of 512 (87%) of patients. Among these 443
patients, CRT was interrupted in 161 (36%) patients during a mean follow-up of 2.5  1.1
years. Reasons included the development of an atrial tachyarrhythmia (18%), loss of left
ventricular capture (10%), diaphragmatic stimulation (2%), loss of right ventricular capture
(2%), infection (1%), intentional discontinuation of CRT (1%), loss of right atrial sensing
(1%), and ventricular oversensing (0.2%). Most patients underwent an intervention that
permitted the reinstitution of CRT, such that only 20 of the 443 patients (5%) experienced
the permanent loss of CRT. Using an intention-to-treat analysis, the long-term retention of
CRT was 83% during the course of 2.5 years.
CONCLUSIONS Cardiac resynchronization therapy is interrupted in more than one-third of patients after the
successful implantation of a CRT-D device. However, CRT can be reinstituted in most
patients and has a high long-term retention rate. Because patients with slower heart rates were
more likely to develop atrial tachyarrhythmias, a dual-chamber rate-modulated pacing mode
(DDDR) may reduce interruptions of CRT. (J Am Coll Cardiol 2004;44:72–7) © 2004 by
the American College of Cardiology Foundationb
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rardiac resynchronization therapy (CRT) has been shown
o be an effective nonpharmacological treatment option for
he subset of patients with advanced congestive heart failure
HF) who have an intraventricular conduction delay and
ystolic dysfunction (1–3). The purpose of this study was to
etermine the frequency and causes of intermittent and
ermanent loss of CRT in patients who have undergone the
uccessful implantation of a transvenous defibrillator that
elivers CRT (CRT-D).
ETHODS
tudy design. The VENTAK CHF/CONTAK CD
iventricular Pacing Study and its results have been de-
cribed in detail elsewhere (4). In brief, the study was a
rospective, randomized, double-blind trial that compared
efibrillator therapy with CRT to defibrillator therapy
ithout CRT in patients who had an indication for defi-
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Manuscript received December 19, 2003; revised manuscript received February 18,2004, accepted March 16, 2004.rillator implantation, medically refractory congestive HF, a
RS duration120 ms, and a left ventricular (LV) ejection
raction 0.35. Patients were required to have a sinus
hythm at the time of enrollment. The study required that
atients were on optimal medical therapy for congestive
F, which included angiotensin-converting enzyme (ACE)
nhibitors. However, patients who had a documented intol-
rance or contraindication to ACE inhibitors were allowed
nrollment. The study was designed in 1997, before many of
he major beta-blocker study results were published. For
his reason, the study did not require patients to be
ndergoing treatment with beta-blockers. Phase I of the
rial was a three-month crossover design, and phase II was
six-month parallel design. Follow-up was performed at
hree-month intervals after randomization.
atients. Five hundred seventeen consecutive patients, who
ere enrolled between February 1999 and December 2000,
nderwent at least one attempt at implantation of a CRT-D
evice. There were 193 patients enrolled in phase I of the trial,
nd 324 patients enrolled in phase II. Five of the 517 patients
ad successful device implantation but had previously under-
one epicardial LV lead placement and were therefore not
ncluded in this analysis. Implantation of a transvenous
RT-D device was successful in 443 (87%) of the remaining
12 patients. The reasons for failure of coronary sinus lead
lacement are summarized in Table 1. The two most common
easons were the inability to cannulate the coronary sinus (n
9) and the inability to obtain a stable pacing site (n  24).
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July 7, 2004:72–7 Retention of CRTThe characteristics of the 443 patients who underwent
uccessful implantation of a transvenous CRT-D device are
ummarized in Table 2. One hundred twenty-three patients
28%) had a history of atrial fibrillation or other supraven-
ricular tachyarrhythmias. Among these patients, amioda-
one had been prescribed in 49%, a sodium channel blocker
n 5%, sotalol in 2%, and a calcium channel blocker in 1%.
he mean follow-up was 2.5  1.1 years (range, 0 to 4
ears).
mplantable device characteristics. Patients received an
mplantable defibrillator system that delivers defibrillator
herapy and CRT pacing. The system has been described in
etail elsewhere (4). The coronary sinus lead is a unipolar
ead that is designed to advance into a branch of the
oronary sinus over a standard 0.014-inch coronary angio-
lasty wire. Tripolar pacing was used for biventricular
apture, and tripolar sensing was used for both ventricular
acing and defibrillation therapy. When CRT was pro-
rammed “on,” the pacing mode was atrial-synchronous
entricular pacing (VDD) with a lower rate of 40 beats/min.
he automatic mode-switch feature (atrial tachycardia re-
ponse) was programmed to “on” in all patients. This feature
witches the pacing mode to a nonatrial tracking mode
ventricular demand pacing, VVI) during atrial tachyar-
hythmias (ATs). Therefore, CRT was not delivered during
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AT  atrial tachyarrhythmia
AV  atrioventricular
CI  confidence interval
CRT  cardiac resynchronization therapy
CRT-D  cardiac resynchronization and defibrillation
therapy
DDI  dual-chamber nonatrial tracking
DDDR  dual-chamber rate-modulated
HR  hazard ratio
LV  left ventricular
RV  right ventricular
VDD  atrial synchronous ventricular
VVI  ventricular demand
VVIR  ventricular rate-modulated
able 1. Causes and Frequencies of Coronary Venous Lead
mplantation Failure
Cause n (%)
nability to cannulate the coronary sinus 29 (6%)
nability to obtain a stable pacing site 24 (5%)
nability to obtain adequate pacing thresholds 6 (1%)
oronary sinus dissection/perforation 5 (1%)
iaphragmatic stimulation that could not be corrected 1 (0.2%)
nability to place a right atrial pacing lead 1 (0.2%)
ransient atrioventricular block caused by guide
catheter
1 (0.2%)
ascular trauma during attempt at venous access 1 (0.2%)
o reason reported 1 (0.2%)
otal 69/512 (13%) vTs when mode switching occurred unless the ventricular
esponse rate was 40 beats/min.
dentification of loss of CRT. To identify patients who
ad interruption of CRT, the study data base was searched
or the following adverse events: pacing mode repro-
rammed to VVI or dual-chamber nonatrial tracking mode
DDI), pacing output increased, lead dislodgement, infec-
ion, or AT. The management of each patient who experi-
nced one of these adverse events was analyzed to determine
hether CRT was interrupted, the specific reason for the
nterruption of therapy, what interventions were performed
o permit the reinstitution of CRT, and whether CRT was
ermanently lost. For each patient who experienced an AT
s an adverse event, CRT was considered interrupted if the
evice automatically switched to a nonatrial tracking mode
nd if the ventricular rate exceeded the lower pacing rate of
he pacemaker.
tatistical analysis. Kaplan-Meier survival curves were
onstructed to represent the rate of permanent loss of CRT
ver time. When CRT was permanently lost, the time of
oss was considered to be the time when CRT was first
iscontinued. Patients were censored from the analysis at
he time of death or cardiac transplantation. Cox regression
nalysis was used to identify predictors of permanent loss of
RT. New York Heart Association functional class was
reated as an ordered categorical variable. All continuous
able 2. Patient Characteristics
ge (yrs) 66  11
ender (male) 83%
VEF 0.21  0.07
YHA class
II 33%
III 58%
IV 9%
RS width (ms) 158  22
AD 69%
BB
Left BBB 57%
IVCD 30%
Right BBB 13%
edications
ACEI/ARB 87%
Beta-blockers 49%
R grade
None 5%
I 57%
II 19%
III 7%
Not reported 12%
istory of atrial tachyarrhythmias
None 73%
Atrial fibrillation 22%
PSVT 3%
Atrial flutter 3%
CEI  angiotensin converting enzyme inhibitors; ARB  angiotensin receptor
lockers; BBB  bundle branch block; CAD  coronary artery disease; IVCD 
ntraventricular conduction delay; LVEF  left ventricular ejection fraction; MR 
itral regurgitation; NYHA  New York Heart Association; PSVT  paroxysmal
upraventricular tachyarrhythmia.ariables were treated as such except for heart rate, which
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Retention of CRT July 7, 2004:72–7as treated as an ordered categorical variable in 10-beats/
in increments. Hazard ratios (HRs) are presented with
5% confidence intervals (CIs). Data are presented as mean
standard deviation. A value p  0.05 was considered
tatistically significant.
ESULTS
nterruption of CRT. Among the 443 patients who un-
erwent a successful CRT-D implant, CRT was interrupted
n 161 (36%) patients at some time during follow-up (Table
). The reasons for interruption of CRT included the
evelopment of atrial fibrillation, atrial flutter, or atrial
achycardia (n  81); loss of LV capture (n  44);
iaphragmatic or phrenic nerve stimulation (n 11); loss of
ight ventricular (RV) capture (n  9); infection requiring
evice explantation (n  5); loss of atrial sensing (n  5);
ntentional discontinuation of CRT as the result of intoler-
nce or worsening symptoms associated with CRT (n  5);
nd ventricular oversensing (n  1).
Variables that independently predicted interruption of
RT as the result of ATs included a previous history of
upraventricular tachyarrhythmia (HR 5.21; 95% CI 3.09 to
.77; p 0.001), a low resting heart rate (HR 1.28 for every
0-beat/min decrease in heart rate; 95% CI 1.04 to 1.59; p
0.006), and the absence of treatment with both a
eta-blocker and an ACE inhibitor (HR 1.92; 95% CI 1.05
o 3.57; p  0.032).
anagement of CRT interruption. Atrial tachyarrhyth-
ias interrupted the delivery of CRT in 81 of 443 (18%)
atients during follow-up. In addition, 26 of these patients
eceived an inappropriate defibrillator shock for an AT. In
8 of the 26 patients, a shock was delivered because the
entricular response rate exceeded the tachycardia detection
ut-off rate of the device, and in eight patients a shock was
elivered because of double counting of the ventricular
lectrogram during ventricular sensing.
The ATs, which were predominantly atrial fibrillation,
ere managed by reprogramming of the device, cardiover-
ion if necessary, and occasionally amiodarone. Of the 81
atients with ATs, 31 successfully returned to normal sinus
Table 3. Causes and Frequencies of Temporar
in 443 Patients Who Underwent Successful Im
Cause
CRT Interrup
n (%)
Atrial tachyarrhythmia 81 (18)
Loss of left ventricular capture 44 (10)
Extracardiac stimulation 11 (2)
Loss of right ventricular capture 9 (2)
Infection/pericarditis 5 (1)
Patient intolerance 5 (1)
Loss of right atrial sensing 5 (1)
Ventricular oversensing 1 (0.2)
Total 161 (36)
CRT  cardiac resynchronization therapy.hythm and had no further recurrences. Forty-one patients fad recurrent AT but continued to receive CRT at least
0% of the time on the basis of the results of the device
istograms that were retrieved between the initial event and
he last follow-up visit. The remaining nine patients exhib-
ted recurrent AT that continued to significantly inhibit the
elivery of CRT. Five of these nine patients underwent
atheter ablation of the atrioventricular junction, and CRT
as restored using a ventricular rate-modulated (VVIR)
acing mode. Two of these patients underwent successful
atheter ablation for atrial flutter and had CRT reinitiated.
ardiac resynchronization therapy could not be restored
ecause of refractory AT in the remaining two patients.
herefore, permanent loss of CRT because of ATs occurred
n 2 of 443 patients and occurred 149  194 days after
mplantation.
Cardiac resynchronization therapy was interrupted in 44
f 443 (10%) patients as a result of the loss of LV capture 74
119 days (median, 13 days) after implantation. The
auses of loss of capture included coronary sinus lead
islodgement in 33 patients, an elevated pacing threshold in
0 patients, and conductor failure in 1 patient. Thirty-two
f these 44 patients underwent an attempted revision of the
oronary sinus lead that was successful in 29 patients.
ardiac resynchronization therapy was restored in each of
he 10 patients with an elevated pacing threshold after the
acing output was increased. Permanent loss of CRT as a
esult of the loss of LV capture occurred in 5 of 443 patients
58  159 days after implantation.
Cardiac resynchronization therapy was interrupted in 11
f 443 (2%) patients 138  158 days after implantation
ecause of diaphragmatic or phrenic nerve stimulation that
ould not be corrected with device reprogramming. In 2 of
he 11 patients, the RV lead was the cause of diaphragmatic
timulation, and the problem resolved after the RV lead was
epositioned. In the remaining nine patients, diaphragmatic
timulation was due to LV pacing. The coronary sinus lead
ad been implanted in a posterior branch vein in a majority
f these nine patients. Six of the nine patients underwent
epositioning of the coronary sinus lead to a more basal
osition or into a more lateral vein, which was successful in
Permanent Loss of CRT During Follow-Up
tation of a Defibrillator With CRT
CRT Restored
n (%)
CRT Permanently Lost
n (%)
79 (18) 2 (0.5)
39 (9) 5 (1)
6 (1) 5 (1)
9 (2) 0
2 (0.5) 3 (1)
1 (0.2) 4 (1)
5 (1) 0
0 1 (0.2)
141 (32) 20 (5)y and
plan
tedour patients. Permanent loss of CRT because of diaphrag-
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July 7, 2004:72–7 Retention of CRTatic or phrenic nerve stimulation occurred in 5 of 443
atients 162  143 days after implantation.
Cardiac resynchronization therapy was interrupted in 9 of
43 (2%) patients because of loss of RV capture (elevated
V pacing threshold in 6 patients and lead dislodgment in
patients) and in 5 of 443 (1%) patients because of atrial
ead dislodgment. Cardiac resynchronization therapy was
estored successfully in all patients after lead revision or
evice reprogramming.
A device infection occurred in 5 of 443 patients 329 
80 days after implantation. Each patient underwent extrac-
ion of the device. Two of the five patients underwent
eimplantation of a CRT-D device. Permanent loss of CRT
ecause of infection occurred in 3 of 443 patients 429  93
ays after implantation.
There were five patients who did not tolerate CRT.
ymptoms that were reported included palpitations, short-
ess of breath, and weakness, which resolved immediately
pon disabling CRT. Three of these patients were felt to
ave left-sided pacemaker syndrome. One patient was
anaged by reprogramming the atrioventricular delay, and
RT was restored. All four of the remaining patients had
RT disabled by programming the pacing mode to VVI.
ermanent loss of CRT occurred in 4 of 443 patients 218
29 days after implantation because of the inability to
olerate CRT. Ventricular oversensing of atrial activity
ccurred in one patient 23 months after implantation. In
his patient, lead revision was unsuccessful, and the lead was
apped.
ermanent loss of CRT. Overall, 20 of 443 patients (5%)
xperienced permanent loss of CRT during follow-up.
hese data are depicted as a survival curve in Figure 1. The
nly independent predictor of permanent loss of therapy
as LV ejection fraction (HR 1.09 for every percentage
oint decrease; 95% CI 1.01 to 1.16; p  0.03). When
atients who underwent an unsuccessful attempt at CRT-D
evice implantation are included in the analysis, the long-
erm retention of CRT is 83% during the time period of 2.5
igure 1. The rate of long-term retention of cardiac resynchronization
herapy (CRT) among the 443 patients who underwent successful implan-
ation of a device that delivers CRT is depicted as a survival curve.ears. tISCUSSION
ain findings. The main findings of this study are that
RT is interrupted in over one-third (36%) of patients after
uccessful implantation of a CRT-D device, and the most
ommon reasons for interruption of CRT are the develop-
ent of ATs (18%) and loss of LV capture (10%). However,
RT can be reinstituted in a high proportion of patients so
hat only 5% of patients who successfully undergo implan-
ation of a CRT device permanently lose CRT. In an
ntention-to-treat analysis, the long-term retention of CRT
s 83% during the course of 2.5 years.
oss of CRT as the result of ATs. In this study, almost
ne fifth of patients who underwent successful implantation
f a defibrillator capable of delivering CRT experienced an
T with a rapid ventricular response, which at least tem-
orarily resulted in the inability to deliver CRT. The high
revalence of atrial fibrillation in this population is not
urprising given the association between atrial fibrillation
nd congestive HF (5), but the finding that atrial fibrillation
as the most common reason for interruption of CRT in
his study emphasizes the importance of maintaining sinus
hythm in patients treated with CRT devices. It is not clear
hether CRT reduces the incidence of atrial fibrillation in
atients with HF. In the present study, only 15 of the 81
atients who experienced an AT that interrupted CRT had
heir AT during the six-month randomization period. Eight
f these 15 patients were among the 222 patients (3.6%)
andomized to CRT, and 7 of these 15 patients were among
he 221 patients (3.2%) randomized to no CRT (p  0.80).
Predictors of interruption of CRT as the result of the
evelopment of ATs in this patient population include a
revious history of AT, a relatively slow resting heart rate,
nd the absence of therapy with both beta-blockers and
CE inhibitors. These findings are consistent with a recent
nalysis of the Studies Of Left Ventricular Dysfunction
SOLVD) study that found that treatment with enalapril
arkedly reduces the risk of development of atrial fibrilla-
ion in patients with LV dysfunction (6). Therefore, al-
hough it is not clear whether the use of both beta-blockers
nd ACE inhibitors directly influence the effectiveness of
RT, their use appears to improve the ability to deliver
RT.
Although a history of ATs appears to predict recurrent
T, it was not associated with the development of ventric-
lar arrhythmias in the present study. The incidence of an
ppropriate defibrillator therapy among the patients with a
istory of ATs was similar to the incidence of an appropriate
efibrillator therapy among patients without a history of
Ts (12.3% vs. 14.9%, respectively; p  0.55).
V pacing lead problems. The second most common
ause of transient loss of CRT in this study was the loss of
V capture, and the most common causes of permanent loss
f CRT were loss of LV capture and extracardiac stimula-
ion. The coronary sinus lead that was used in the study was
he first transvenous LV lead that was commercially avail-
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Retention of CRT July 7, 2004:72–7ble from Guidant Inc. (St. Paul, Minnesota). The adverse
vent rates observed with this pacing lead are similar to that
f other commercially available coronary venous leads.
verall, the proportion of patients who required a surgical
ntervention to restore LV capture in this study was 34 of
43 (8%), which is similar to proportions reported in the
ummaries of Safety and Effectiveness published by the
.S. Food and Drug Administration for coronary venous
eads implanted in the Multicenter InSync Randomized
linical Evaluation (MIRACLE) trial (37 of 532 patients;
%) and in the MIRACLE ICD trial (37 of 351 patients;
1%) (7,8). In addition, the proportion of patients who
equired a surgical intervention in this study to correct
xtracardiac stimulation was 11 of 443 (3%), which is
omparable with the proportions in the MIRACLE trial (4
f 532 patients; 1%) and in the MIRACLE ICD trial (12 of
51 patients; 3%). Newer lead designs that include different
xation methods and bipolar electrodes may improve the
ong-term ability to deliver CRT by improving pacing
hresholds, reducing dislodgements, and avoiding extracar-
iac stimulation.
The likelihood that a significant number of patients had
nrecognized intermittent loss of biventricular capture is
ow. The potential for unrecognized loss of LV capture has
een examined previously by a comparison of the LV pacing
hresholds and the programmed device pacing outputs (9).
he results revealed that investigators programmed devices
onservatively by using a 200% safety margin instead of the
ustomary 100% safety margin that is used with conven-
ional implantable pacemakers and defibrillators. In addi-
ion, biventricular capture was verified during daily activities
sing periodic Holter monitoring and during exercise using
ardiopulmonary exercise testing.
ntolerance to CRT. Cardiac resynchronization therapy
as discontinued permanently in 4 of 443 patients who were
hought by their physicians to be intolerant of CRT. It is
nteresting that in the Multisite Stimulation in Cardiomy-
pathy trial, approximately 4% of patients who were asked
hether they preferred CRT or no CRT actually preferred
o CRT (10). Potential explanations for intolerance to
trial-biventricular pacing include left-sided pacemaker syn-
rome and aggravation of ventricular dyssynchrony. Al-
hough intolerance to CRT is uncommon, its occurrence
mphasizes the need for careful follow-up for patients who
re treated with CRT.
omparison with pharmacologic therapy. The standard
harmacological therapy for congestive HF includes beta-
lockers, ACE inhibitors, and spironolactone. The discon-
inuation rate for beta-blockers is at least 6% per year. In the
.S. Carvedilol Heart Failure Study, 6% of patients failed to
omplete the open-label run-in period with carvedilol be-
ause of adverse events, and carvedilol was discontinued in
n additional 6% of patients during the double-blind treat-
ent phase over a median follow-up period of 6.5 months
11). In the Carvedilol Or Metoprolol European Trial
COMET), a randomized trial that compared carvedilolith metoprolol in patients with chronic HF, the study drug
as permanently stopped in 32% of patients in the carve-
ilol group and 32% in the metoprolol group during a mean
ollow-up of 58 months (12). Assuming that study drug
iscontinuation occurred steadily over time, the average
iscontinuation rate was approximately 6% per year. In the
ssessment of Treatment with Lisinopril And Survival
ATLAS) trial, lisinopril was discontinued in 17% of
atients because of side effects in the high-dose group and in
8% of patients in the low-dose group during a follow-up
hat ranged from 39 to 58 months (13). The high discon-
inuation rate in the ATLAS trial occurred despite nearly
0% of patients having previously tolerated some dose of an
CE inhibitor before entering the study. For captopril, the
iscontinuation rate was 15% during a median follow-up
eriod of 555 days in the Evaluation of Losartan In The
lderly (ELITE) trial (14). Spironolactone appears to be
airly well tolerated and was discontinued in approximately
% of patients in the Randomized Aldactone Evaluation
tudy (RALES) trial (15). The long-term retention of CRT
n patients who underwent an attempt at implantation of a
RT-D device was 83% over 2.5 years is comparable with
he long-term retention of pharmacological therapy for HF.
Compliance is another factor that is associated with the
ong-term successful delivery of HF therapy. Although
RT has the advantage over pharmacologic HF therapy of
eing less dependent on daily patient compliance, this study
ighlights the importance of compliance with device
ollow-up for the successful delivery of CRT.
tudy limitations. The primary limitation of the present
tudy is that loss of CRT was evaluated in patients who
eceived CRT that was delivered by a specific device and
pecific coronary venous lead. Although some of the causes
f loss of CRT that were identified, such as phrenic nerve
timulation, may be specific to the device that was im-
lanted, most of the results of this study are likely to apply
o any device that delivers CRT.
linical implications. The results of this study suggest
hat prevention of atrial fibrillation would significantly
mprove the ability to deliver CRT in patients with HF.
he protocol for the present study required that the
acing mode be programmed to VDD so that the effect of
RT could be determined without the confounding
ffect of an increase in heart rate. Because patients with
lower heart rates were more likely to develop ATs in this
tudy, a CRT trial that compares a dual-chamber rate-
odulated (DDDR) pacing mode that increases the atrial
ate to the conventional VDD pacing mode seems logical.
n evaluation of pacing algorithms that may prevent
trial fibrillation in this HF population is also needed.
eprint requests and correspondence: Dr. Bradley P. Knight,
niversity of Chicago Hospitals, Center for Advanced Medicine,
C 9024, 5758 South Maryland Avenue, Chicago, Illinois 60637.
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